Popular Articles

Total Swine Flu A(H1N1) Human Infection Cases Reach 7,447 In The United Kingdom
The Health Protection Agency (HPA), UK, informed yesterday 3rd July, 2009, in its weekly update that the total number of confirmed human cases of Swine Flu A(H1N1) infection has reached 7,447. British health authorities estimate that the figure will be over 100,000 by the end of this summer.

MorphoSys Reports Filing For Phase 1b/2a Trial For Its Lead Program MOR103 In Rheumatoid Arthritis
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced that the Company has submitted an application for the authorization of a phase 1b/2a clinical study in patients with active rheumatoid arthritis (RA) for its lead drug MOR103, a fully human HuCAL-derived monoclonal antibody directed against Granulocyte Macrophage-Colony Stimulating Factor. The trial, which will be conducted in multiple centers in several European countries, is expected to enroll 135 patients in total beginning in the second half of 2009. Additionally, the Company today reported positive results from the phase 1 clinical study for MOR103 in healthy volunteers. The results of this study indicate that MOR103 is generally safe and well tolerated at all doses administered.
News of the day
Juggling Cells Using High-Precision Laser Tweezers
Researchers at the University of Gothenburg, Sweden, have developed a new method to study single cells while exposing them to controlled environmental changes. The unique method, where a set of laser tweezers move the cell around in a microscopic channel system, allows the researchers to study how single cells react to stress induced by a constantly changing environment.
Endocrinology

Internists And Other Physician Groups Support Comparative Effectiveness Provisions In Proposed Legislation

The American College of Physicians (ACP) joined with two other physician groups to offer strong support for the Comparative Effectiveness Research (CER) provisions included in the Tri-Committee health reform bill about to be considered in the House. The Tri-Committee, which unveiled its proposed legislation on June 19, is made up of the House Ways and Means, Energy and Commerce, and Education and Labor Committees. Today"s support was provided in a letter to the chairmen and ranking members of the three committees. The organizations - ACP, the American Academy of Family Physicians (AAFP) and the Society of General Internal Medicine (SGIM) - represent more than 200,000 physicians who treat patients every day, many of whom have multiple chronic conditions. "We know the value of having scientifically valid information available that permits physicians and their patients to make informed decisions on the most effective and appropriate treatment in individual cases. We also firmly believe that patient care will benefit if coverage decisions are informed by the best available science, including evidence on the clinical effectiveness of different treatments," said Jim King, MD, FAAFP, board chair of AAFP, Joseph W. Stubbs, MD, FACP, president of ACP and Nancy Rigotti, MD, FACP, president of SGIM "Comparative effectiveness research brings to the patient and physician the best chance of providing the right treatment to each patient in the most safe and effective manner. We know that better information on which treatments are most effective leads to better patient outcomes, less suffering, and more efficient use of limited healthcare res. Moreover, we agree with the approach of your bill, which makes clear the importance that this information must be the result of scientifically valid research, emanating from a trusted and dedicated solely to the development of comparative effectiveness research based on the best available science and through a transparent process," the letter continued. "We have great respect for the incredibly hard work your committees have undertaken in the enormous and complex objective of healthcare reform. As the bill moves through the House and eventually into a Conference Committee with the Senate, we urge you to hold fast to your positions on CER that will maintain it as a scientifically-based research initiative designed to benefit patients. CER should not be subjected to arbitrary legislative limits on use that could harm patients by denying them, their physicians, and their health plans with access to the best scientific evidence to improve the care patients receive." "Thank you for considering our views. We look forward to continuing to work with you in the weeks and months ahead as you endeavor to provide the American people with a healthcare system, with CER, that will work to their great benefit," the letter ended. The American College of Physicians


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):